Profound Medical (OTCQX:PRFMF; TSXV:PRN) has agreed to expand an existing collaboration with Royal Philips (NYSE:PHG; AEX:PHIA) and acquire Philips’ Sonalleve MR-HIFU business, establishing Profound as a market leader in magnetic resonance (MR) ultrasound ablation therapy.Read More
Profound Medical (OTCQX:PRFMF;TSXV:PRN) announced the first TULSA-PRO patient paid procedure has been successfully conducted at the ALTA Klinik in Bielefeld, Germany under the supervision of Dr. Agron Lumiani.Read More
Profound Medical (TSX-V:PRN) has completed a bought deal offering of 15.82 million common shares at a price of $1.10 each for gross proceeds of about $17.4-million.
The offering was completed through a syndicate of underwriters led by GMP Securities, and included Echelon Wealth Partners and Mackie Research Capital.Read More
Profound Medical (TSX-V:PRN) has entered into an agreement with a syndicate of underwriters, led by GMP Securities, for a bought deal of 15.82 million common shares at a price of $1.10 each for gross proceeds of $17.4-million.
The company has agreed to grant underwriters an overallotment option to purchase up to an additional 2,373,000 common shares at the same price for 30 days following closing. The offering is expected to close on Nov. 14, subject to regulatory approvals.Read More
Stereotaxis (NASDAQ:STXS) has signed definitive agreements for multiple transactions that significantly strengthen its financial position and help accelerate and enhance its strategic market growth initiatives.
The transactions include an equity financing of $24-million, satisfaction in full of outstanding debt to Healthcare Royalty Partners for a payment of $13-million, and the addition to the board of three new directors with significant operational and financial experience in the medical device industry.Read More